PAC Partners Equity Research Report
Sydney, May 17, 2019 AEST (ABN Newswire) - In the lead up to World IBD Day, this coming Sunday, 19th May, PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (
ASX:ANR) (ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.
"World IBD Day - Sunday 19 May - ANR offers natural treatment "
Key Points
- Sunday 19 May marks five years since the first World IBD Day. The size of the market is staggering with more than 1 person in 10 living with severe gut health conditions.
- Over the next six months ANR has a series of key milestones with in vitro, animal and human clinical trials. These will extend the 30 years of support for use of natural bromelain for human gut health treatment.
- ANR is likely to be able to claim the trifecta of: stopping pro-inflammatory bacteria adhering to the gut wall; reducing inflammation of the gut; and kick-starting the cells of the gut to repair the gut lining during and after disease. Doing all this with a natural product is a genuine game changer across human gut health. Each of the next six months will show steps to ANR's success.
- It is easy to forget that Zoetis, #1 animal health company, has already snapped up the global rights to bromelain for scour/diarrhea in farm animals with milestones and royalties to ANR. Zoetis' validation and Australian regulatory OK are significant. China's current African swine fever epidemic has also put animal health strategies on the front page of global press.
To view the report, please visit:
http://abnnewswire.net/lnk/G90K33Z8
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
